Abstract 292P
Background
Shared decision making (SDM) is a dynamic clinical process where physicians and patients mutually and actively share information and collaborate to discuss available evidence during treatment decisions, and where patients are supported to consider options in order to achieve informed preferences. It has become a hallmark of patient-centered care and communication which highlights physician-patient relationship as the core in improving health outcomes, and refers to the type of care that is responsive to the individual needs and preferences of the patient, ensuring that clinical decisions are aligned with his or her values. In cancer care, preference-sensitive decisions range from screening decisions, to treatment decisions, and to end-of-life care. There is little experience with SDM in the Philippines and its integration into the practice of Oncology. The objective of this study was to explore patient perception and evaluate the extent to which a shared decision-making process is implemented in clinical encounters at the Cancer Institute adult outpatient clinics of the Philippine General Hospital.
Methods
The SDM Q-9 Filipino version was administered to 267 patients who were consulting at the adult outpatient clinics of the Cancer Institute over one month.
Results
More than 90% of the patients surveyed agreed that shared decision-making process were being practiced at the Cancer Institute adult outpatient clinics. Of these, almost half of the respondents answered “somewhat agreed” in all items, except for the domain which sought if the physician helped the patient to understand information which showed stronger trend towards agreement. Notably, the domains involving identification of preferences and shared decision showed weaker trend towards agreement, with 5% and 7% of patients surveyed disagreeing that these steps were being observed in practice, respectively. This indicated that among the nine items of the SDM Q-9, these areas required the most strengthening.
Conclusions
In this study, the investigators observed that cancer patients agreed that shared decision making was being practiced during their clinical encounters with their respective physicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session